Mainz Biomed Enters into Technology Partnership with EDX Medical Group
Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK.
'We are delighted to join forces with EDX Medical Limited to improve access to high-quality cancer diagnostics in the UK,' said Guido Baechler, Chief Executive Officer of Mainz Biomed. 'By merging our expertise in molecular diagnostics with EDX Medical's excellent capabilities, we can provide a highly reliable and meaningful contribution to early cancer detection and prevention.'
Dr Mike Hudson, CEO of EDX Medical, said: 'We are dedicated to making the very best diagnostic tests available to patients and healthcare professionals and are continuously looking to improve the performance of cancer testing by incorporating molecular biomarkers that can transform early cancer detection. We are delighted to form this technology partnership which will help us achieve this aim.'
Please visit Mainz Biomed's official website for investors at mainzbiomed.com/investors/ for more information
Please follow us to stay up to date:LinkedInX (Previously Twitter)Facebook
About Mainz Biomed NVMainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
About EDX Medical Group EDX Medical Group plc is headquartered in Cambridge, UK, and is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson. By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally. For more information, please visit www.edxmedical.com.
For media inquiries as to Mainz Biomed:MC Services AGMaximilian Schur / Simone Neeten+49 211 529252 20mainzbiomed@mc-services.eu For investor inquiries, please contact ir@mainzbiomed.com
For media inquiries as to EDX Medical Group:Media House InternationalRamsay Smith+44 (0)7788 414856ramsay@mediahouse.co.ukGary McQueen+44 (0)7834 694609gary@mediahouse.co.uk
Forward-Looking StatementsCertain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'expect', 'estimate', 'plan', 'outlook', and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the 'SEC') by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Liverpool REJECTED Alexander Isak agreement
Liverpool fans have known for a long time that asking prices are a rough valuation of a player. Teams rarely get the exact amount they're after. A negotiation takes place and eventually, each side has to make a compromise in order to get what they want. It's a fundamental business principle. 🔴 Shop the LFC 2025/26 adidas home range 🚨2025/26 LFC x adidas range🚨 LFC x adidas Shop the away range TODAY LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! Valuations alongside 'gentlemen's agreements' and 'promises' are easily bypassed and it's easy for teams to become hypocritical - this is an idea that Anfield Watch has explored in more depth through the prism of Newcastle's approach for Yohan Wissa, in connection with their Alexander Isak situation. Earlier this year, in a high profile move for Florian Wirtz, the Reds successfully managed to agree a deal of £100m plus £16m in add-ons instead of caving in and paying Leverkusen's £126m valuation. As such, it should come at no surprise that Isak was never going to leave for £150m and while a deal looks to be off this summer, insider information has been revealed regarding how much Newcastle were willing to sell him for, had they have subsequently brought in a new striker this summer. 13% discount for Isak was available According to Craig Hope, the 'not for sale' stance coming out of Tyneside was actually a massive lie. In his latest report, he said: "The club have pursued alternatives to Isak all summer. Had one of Joao Pedro, Liam Delap, Hugo Ekitike or Benjamin Sesko been signed, Newcastle would have explored his sale. "Sources believe a deal in the region of £130m plus add-ons would, in the end, have seen an agreement reached between them and Liverpool. However, with each passing day and target gone, that likelihood has decreased." As such, the Reds would have needed to put up more money, but both sides would have compromised, which is exactly how all pieces of transfer business unfold. As said, it's a negotiation. To suggest that Liverpool have rejected an agreement to sign him is perhaps a little twisted, since the club had received no encouragement that a new bid would have been successful, new strikers needed to be signed at Newcastle before the green light to his move could have been signalled. But since that's not happening, you can't help but wonder if a £130m bid would at all be tempting at this stage, despite him not having been replaced. After all, since he's gone AWOL, the Magpies don't exactly have a striker at the club despite keeping him. His prerogative is to not play for them again. On the basis that we've been left waiting so long for a second bid, it would certainly be wishful thinking to consider a move like that being sanctioned by FSG, which in turn would be Liverpool rejecting an attempt at reaching an agreement, primarily because of how far-fetched it would be. Reason currently suggests that January might be the most opportune moment to consider Isak again, once he and Newcastle have had a chance to stew on their incredibly toxic circumstances. A further discounted move from the £150m pipe-dream might then be promising and Liverpool would have a lot more time to finalise all the details, with Newcastle more open to hearing their approach.
Yahoo
6 minutes ago
- Yahoo
Why Baidu Stock Wilted on Wednesday
Key Points The Chinese tech industry giant reported its second-quarter results that morning. It posted declines in both revenue and adjusted profitability. 10 stocks we like better than Baidu › Veteran Chinese tech giant Baidu (NASDAQ: BIDU) looked rather tired to equity investors on Wednesday. They didn't seem wowed by the company's latest earnings release and expressed this by collectively trading their American depositary shares (ADS) down by almost 3%. This was a steeper fall than the 0.2% endured by the bellwether S&P 500 index. Top- and bottom-line slides Baidu's second-quarter results, published well before market open that day, revealed that the company's revenue slumped by 4% year over year to 32.7 billion yuan ($4.55 billion). That was slightly below the consensus analyst estimate of 32.9 billion yuan ($4.58 billion). The decline and miss might have been more pronounced had it not been for the company's artificial intelligence (AI)-boosted offerings. Baidu quoted CEO Robin Li as saying that its AI Cloud business "continued to deliver robust and healthy revenue growth, supported by our strengthening full-stack AI capabilities and comprehensive end-to-end AI products and solutions." It didn't help push the bottom line higher, however, as non-GAAP (adjusted) net income fell by 35% to just under 4.8 billion yuan ($668 million). On a per-ADS basis, the company's profitability was 13.58 yuan ($1.89). On the bright side, this was a bit higher than the average analyst estimate of 13.33 yuan ($1.86) per ADS. Motoring into a better future? In its earnings release, Baidu pointed to AI as a potential engine of growth. On the subject of engines, it also clearly has high hopes for the robotaxis coming from its mobility unit, Apollo Go. It said that it is a leading company in robotaxi markets with both left- and right-hand drive regimes. Should you buy stock in Baidu right now? Before you buy stock in Baidu, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Baidu wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Baidu. The Motley Fool has a disclosure policy. Why Baidu Stock Wilted on Wednesday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
8 minutes ago
- Business Insider
Parts of Europe are suspending postal shipments to the US — and your order may not arrive
Postal services operated by Norway, Sweden, Denmark, and Belgium — Posten Bring, PostNord, and bpost — said they will suspend parcel shipments to the US ahead of the end of a customs exemption that allows low-value packages to enter the country duty-free. The conundrum facing postal operators comes as the Trump administration prepares to suspend the " de minimis" exemption starting on August 29. The exemption used to allow international shipments under $800 to cross the border with minimal paperwork and no duties. Now, these shipments will face tariffs, and not every operator can handle the customs declaration paperwork, have a payment mechanism in place, or be responsible for returns should a receiver refuse to pay tariffs. It's unclear when the temporary freeze on shipments will resume. "Due to the short timeframe to adapt to the new specific requirements, PostNord will temporarily halt shipments to the United States and Puerto Rico until a compliant solution has been developed and implemented," wrote the operator owned by the Swedish and Danish governments in a statement on Wednesday. Separately, Posten Bring, Norway's primary postal provider operated by the government, said in a statement that postal services have not been given clear instructions and solutions on how the duties will be paid or who would be responsible for returns. Therefore, Posten Bring sees suspension as the "only option." All three European postal services will suspend shipments starting August 23, which applies to all packages other than letters. This means that if you have a pending purchase that is not shipped by the deadline, your seller may need to cancel your order or arrange alternatives. But even if you're not purchasing from these specific European countries, your shopping options might still dwindle and become more costly. Etsy, the US e-commerce giant and a hub for independent crafters, posted a notice Wednesday that shipping label purchases for Australia Post, Canada Post, Evri, and Royal Mail for US-bound packages will be temporarily suspended starting August 25. Etsy wrote in a statement that these operators are unable to support prepaid duties at the moment, which may result in a large number of rejected packages due to unpaid duties and surprise costs for buyers not listed at checkout. Across social media platforms, many independent sellers based in the UK are also announcing that they can no longer support orders to the US, citing the introduction of an $80 flat fee plus handling charges for using Royal Mail to ship parcels to the US. "We hope to resume shipping as soon as we can, but we really don't want our customers to be hit with an $80+ fee," wrote the Citrine Circle, a UK-based crystal shop, on Instagram. "It feels like the world is getting smaller and smaller."
